Literature DB >> 32770271

Presence of purpura is related to active inflammation in association with IL-5 in eosinophilic granulomatosis with polyangiitis.

Hiroshi Kataoka1, Tomoko Tomita2, Makoto Kondo2, Masaya Mukai2.   

Abstract

Eosinophilic granulomatosis with polyangiitis (EGPA) is a relatively rare necrotizing vasculitis that causes asthma, nasal involvement, peripheral nerve disturbance, renal disorder, and cutaneous lesions like purpura and is characterized by eosinophil infiltration into the damaged tissue. Purpura is the most common cutaneous lesion, but it remains unknown whether this skin lesion is associated with disease activity of EGPA and laboratory data including interleukin (IL)-5, a target cytokine of this disease. We conducted a search of our hospital electronic records for cases of EGPA from the last 10 years. Symptoms related to EGPA (fever, asthma, nasal and cutaneous manifestations, neuropathy), the Birmingham Vasculitis Activity Score (BVAS), and laboratory parameters, such as eosinophil count, urinalysis, antineutrophil cytoplasmic antibody (ANCA), CRP, IgE and IL-5, before and during treatment were compared among the eligible cases. A total of 28 EGPA patients (21 females and 7 males) were selected. Almost all developed peripheral neuropathy. Fever occurred in 25%, nasal symptoms in 38.1% and purpura in 44%. Glomerulonephritis developed in 7.7%. One patient had cardiac involvement (3.6%). The laboratory data showed a marked increase in peripheral eosinophil count, CRP, serum IgE and serum IL-5. ANCA was positive in 15.4%. In the univariate analysis, presence of purpura was associated with increased CRP and IL-5, and high BVAS score. Multivariate analysis revealed a robust relationship between purpura and CRP. Our findings showed that presence of purpura was associated with increased CRP and IL-5, and high disease activity in EGPA.

Entities:  

Keywords:  Antineutrophil cytoplasmic antibody; Churg–Strauss syndrome; Eosinophils; Interleukin-5; Purpura

Year:  2020        PMID: 32770271      PMCID: PMC7835155          DOI: 10.1007/s00296-020-04672-8

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  22 in total

1.  Cutaneous lesions of allergic granulomatosis; a histopathologic study.

Authors:  L STRAUSS; J CHURG; F G ZAK
Journal:  J Invest Dermatol       Date:  1951-12       Impact factor: 8.551

2.  Value of commonly measured laboratory tests as biomarkers of disease activity and predictors of relapse in eosinophilic granulomatosis with polyangiitis.

Authors:  Peter C Grayson; Paul A Monach; Christian Pagnoux; David Cuthbertson; Simon Carette; Gary S Hoffman; Nader A Khalidi; Curry L Koening; Carol A Langford; Kathleen Maksimowicz-McKinnon; Philip Seo; Ulrich Specks; Steven R Ytterberg; Peter A Merkel
Journal:  Rheumatology (Oxford)       Date:  2014-11-17       Impact factor: 7.580

3.  Eomesodermin controls interleukin-5 production in memory T helper 2 cells through inhibition of activity of the transcription factor GATA3.

Authors:  Yusuke Endo; Chiaki Iwamura; Makoto Kuwahara; Akane Suzuki; Kaoru Sugaya; Damon J Tumes; Koji Tokoyoda; Hiroyuki Hosokawa; Masakatsu Yamashita; Toshinori Nakayama
Journal:  Immunity       Date:  2011-11-23       Impact factor: 31.745

4.  The interleukin-33-p38 kinase axis confers memory T helper 2 cell pathogenicity in the airway.

Authors:  Yusuke Endo; Kiyoshi Hirahara; Tomohisa Iinuma; Kenta Shinoda; Damon J Tumes; Hikari K Asou; Nao Matsugae; Kazushige Obata-Ninomiya; Heizaburo Yamamoto; Shinichiro Motohashi; Keisuke Oboki; Susumu Nakae; Hirohisa Saito; Yoshitaka Okamoto; Toshinori Nakayama
Journal:  Immunity       Date:  2015-02-17       Impact factor: 31.745

5.  Initial cutaneous manifestations consistent with mononeuropathy multiplex in Churg-Strauss syndrome.

Authors:  Tamihiro Kawakami; Yoshinao Soma; Kanade Kawasaki; Ayumi Kawase; Masako Mizoguchi
Journal:  Arch Dermatol       Date:  2005-07

6.  Longterm Prognosis of 121 Patients with Eosinophilic Granulomatosis with Polyangiitis in Japan.

Authors:  Naomi Tsurikisawa; Chiyako Oshikata; Arisa Kinoshita; Takahiro Tsuburai; Hiroshi Saito
Journal:  J Rheumatol       Date:  2017-06-01       Impact factor: 4.666

7.  Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort.

Authors:  Cloé Comarmond; Christian Pagnoux; Mehdi Khellaf; Jean-François Cordier; Mohamed Hamidou; Jean-François Viallard; François Maurier; Stéphane Jouneau; Boris Bienvenu; Xavier Puéchal; Olivier Aumaître; Guillaume Le Guenno; Alain Le Quellec; Ramiro Cevallos; Olivier Fain; Bertrand Godeau; Raphaèle Seror; Bertrand Dunogué; Alfred Mahr; Philippe Guilpain; Pascal Cohen; Achille Aouba; Luc Mouthon; Loïc Guillevin
Journal:  Arthritis Rheum       Date:  2013-01

Review 8.  Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): state of the art.

Authors:  A Vaglio; C Buzio; J Zwerina
Journal:  Allergy       Date:  2013-01-18       Impact factor: 13.146

9.  Eosinophil extracellular DNA trap cell death mediates lytic release of free secretion-competent eosinophil granules in humans.

Authors:  Shigeharu Ueki; Rossana C N Melo; Ionita Ghiran; Lisa A Spencer; Ann M Dvorak; Peter F Weller
Journal:  Blood       Date:  2013-01-09       Impact factor: 22.113

10.  Type 2 innate lymphoid cells control eosinophil homeostasis.

Authors:  Jesse C Nussbaum; Steven J Van Dyken; Jakob von Moltke; Laurence E Cheng; Alexander Mohapatra; Ari B Molofsky; Emily E Thornton; Matthew F Krummel; Ajay Chawla; Hong-Erh Liang; Richard M Locksley
Journal:  Nature       Date:  2013-09-15       Impact factor: 49.962

View more
  1 in total

1.  Eosinophil ETosis-Mediated Release of Galectin-10 in Eosinophilic Granulomatosis With Polyangiitis.

Authors:  Mineyo Fukuchi; Yosuke Kamide; Shigeharu Ueki; Yui Miyabe; Yasunori Konno; Nobuyuki Oka; Hiroki Takeuchi; Souichi Koyota; Makoto Hirokawa; Takechiyo Yamada; Rossana C N Melo; Peter F Weller; Masami Taniguchi
Journal:  Arthritis Rheumatol       Date:  2021-08-11       Impact factor: 15.483

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.